AHRMM Issues & Legislative Committee

Articles

Issues & Trends, Advocacy & Public Policy, Legislation and Legislative Advocacy, Risk Management, Supply chain management, Medical Device Regulation, Medical Device Safety

I&L Committee Topic: Ethylene Oxide (EtO) Sterilization

AHRMM Issues & Legislative (I&L) Committee identifies, reviews and follows the regulatory, environmental, quality of service and standards matters that impact the health care supply chain field. Each I&L Committee member closely monitors an important topic and compiles an update with useful information to help AHRMM members stay ahead of policy issues that affect their work and health care organization.

Analytics & Research, Cost Management, Cost, Quality and Outcomes (CQO) Movement, Regulations and Regulatory Advocacy, Performance Metrics

Value Based Purchasing Awareness Brief

This Awareness Brief provides a high level summary understanding of value based purchasing. The Hospital Value Based Purchasing (VBP) Program adjusts hospitals’ payments based on their performance in four domains that reflect hospital cost, quality and outcomes. This calendar year, 2016, is the Performance Measurement Period for the FY 2018 VBP Program.

Analytics & Research, Benchmarking, Cost Management, Reprocessing Medical Devices, Performance Metrics

AHRMM Statement on Comparative Effectiveness

AHRMM supports the concept and use of Comparative Effectiveness Research (CER) to provide evidence-based data to help inform purchasing decisions. CER is designed to support healthcare decisions by providing objective conclusions after comparing the effectiveness, benefits, and potential harm of various medical equipment, devices, or treatment options for specific episodes of care or states of disease.
 
By using objective data provided by CER, healthcare supply chain professionals have the ability to:

Cost, Quality and Outcomes (CQO) Movement, Logistics

UDI and Adverse Event Reporting Advisory

The Food and Drug Administration (FDA) UDI system is being phased in over several years. The first sunrise date (certain Class III devices) occurred 09/24/14. Recognizing UDI implementation will take time, healthcare supply chain and risk management professionals should be aware of already-implemented changes in the FDA’s adverse event reporting methodology. One of the changes required immediately is the use of the UDI in adverse event reporting.